Tempus delivered fourth-quarter revenue of $367.2 million, an 83.0% increase year-over-year, driven by Diagnostics revenue of $266.9 million (121.6% growth) and Data & Applications revenue of $100.4 million (25.1% growth). Gross profit rose 94.7% to $237.7 million, net loss widened to $54.2 million, and adjusted EBITDA improved to $12.9 million. For full-year 2025, revenue reached $1.27 billion (83.4% growth), with Diagnostics at $955.4 million and Data & Applications at $316.4 million, while net loss was $245.0 million and adjusted EBITDA loss narrowed to $7.4 million.

During 2025, Tempus launched Paige Predict, an AI-powered pathology suite that predicts 123 biomarkers across 16 cancer types, and reported study results showing its Immune Profile Score improved immunotherapy response predictions, identifying new potential responders in colorectal and rare cancers. The company also entered a multi-year molecular profiling collaboration with NYU Langone Health and was selected by Northwestern Medicine to expand genomic testing across its oncology network.

Tempus ended 2025 with $759.7 million in cash and marketable securities, over $1.1 billion in total remaining contract value, and 126% net revenue retention. Management issued guidance for 2026, targeting $1.59 billion in revenue and approximately $65 million in adjusted EBITDA, reflecting confidence in continued high-growth diagnostics and data business performance.